These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 908027)

  • 1. Metabolic disposition of antipyrine in patients with lung cancer.
    Tschanz C; Hignite CE; Huffman DH; Azarnoff DL
    Cancer Res; 1977 Nov; 37(11):3881-6. PubMed ID: 908027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of age on antipyrine metabolism in patients with gastric cancer.
    Higuchi T; Nakamura T; Uchino H
    J Natl Cancer Inst; 1980 Nov; 65(5):897-900. PubMed ID: 6933259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipyrine metabolism in lung cancer patients and their relatives.
    Radzikowska E; Gazdzik W; Rowińska-Zakrzewska E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():297-308. PubMed ID: 9337547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine metabolism and bronchogenic carcinoma.
    Ambre J; Graeff D; Bures F; Haupt D; Deason K
    J Med; 1977; 8(1):57-70. PubMed ID: 267157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipyrine metabolism in lung cancer patients].
    Radzikowska E; Gaździk W; Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 1993; 61(9-10):496-502. PubMed ID: 8111326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine.
    Higuchi T; Nakamura T; Uchino H
    Gan; 1978 Dec; 69(6):753-6. PubMed ID: 750270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
    Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
    J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial prospective evaluation of cancer incidence in relation to metabolism of antipyrine and family history in patients with lung cancer].
    Radzikowska E; Oniszh K; Chojak E
    Pneumonol Alergol Pol; 1996; 64(1-2):45-9. PubMed ID: 8630464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
    Groen K; Breimer DD; van Bezooijen CF
    Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
    Adedoyin A; Aarons L; Houston JB
    Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR; Egan JM; Dickinson TH; Carrum G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized prospective controlled study of the metabolism and hepatotoxicity of halothane in humans.
    Cousins MJ; Gourlay GK; Knights KM; Hall PD; Lunam CA; O'Brien P
    Anesth Analg; 1987 Apr; 66(4):299-308. PubMed ID: 3565792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
    van den Broek JM; Teunissen MW; Breimer DD
    Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.